Abstract

Creatine supplementation is widely used in sports and increasingly popular among exercising individuals. Although the physiological role of creatine has been extensively studied, the creatine biology in pathological conditions remains poorly understood. Here we report that exogenous creatine supplementation promotes tumor metastasis via platelet activation mechanism in various mouse models and humans. Mechanistically, creatine supplementation increases megakaryocyte creatine levels and upregulates creatine kinase B (CKB). Unbiased phosphoproteomics reveals that a CKB-downstream, non-canonical STAT5B phosphorylation instigates various platelet functional genes, leading to hyperactive, metastasis-promoting platelets. Megakaryocyte-specific knockout of the creatine transporter Slc6a8 or Stat5b , as well as pharmacological inhibition of STAT5, ablates the creatine-augmented platelet hyperactivity and prevents consequent metastasis in mice. Importantly, creatine supplementation in healthy volunteers results in hyperactive peripheral platelets that increase metastasis risks. Together, our study sheds mechanistic insights into the creatine-induced metastasis and provides an anti-metastatic therapeutic paradigm by targeting megakaryocyte creatine metabolism. How diet regulates cancer progression and therapeutic response is not completely understood. Here, the authors show that creatine supplementation promotes tumor metastasis by inducing hyperactive platelets in cancer models.